ATE207930T1 - Gereinigtes gp120, in dem seine natürliche konformation erhalten bleibt - Google Patents

Gereinigtes gp120, in dem seine natürliche konformation erhalten bleibt

Info

Publication number
ATE207930T1
ATE207930T1 AT91906615T AT91906615T ATE207930T1 AT E207930 T1 ATE207930 T1 AT E207930T1 AT 91906615 T AT91906615 T AT 91906615T AT 91906615 T AT91906615 T AT 91906615T AT E207930 T1 ATE207930 T1 AT E207930T1
Authority
AT
Austria
Prior art keywords
protein
hiv
binding affinity
substantially identical
properties substantially
Prior art date
Application number
AT91906615T
Other languages
English (en)
Inventor
Nancy L Haigwood
Carl J Scandella
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23949786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE207930(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE207930T1 publication Critical patent/ATE207930T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cookers (AREA)
  • Gloves (AREA)
  • Table Devices Or Equipment (AREA)
AT91906615T 1990-03-09 1991-03-08 Gereinigtes gp120, in dem seine natürliche konformation erhalten bleibt ATE207930T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49085890A 1990-03-09 1990-03-09
PCT/US1991/001484 WO1991013906A1 (en) 1990-03-09 1991-03-08 PURIFIED gp120 COMPOSITION RETAINING NATURAL CONFORMATION

Publications (1)

Publication Number Publication Date
ATE207930T1 true ATE207930T1 (de) 2001-11-15

Family

ID=23949786

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91906615T ATE207930T1 (de) 1990-03-09 1991-03-08 Gereinigtes gp120, in dem seine natürliche konformation erhalten bleibt

Country Status (8)

Country Link
EP (1) EP0519001B2 (de)
JP (2) JP2624894B2 (de)
AT (1) ATE207930T1 (de)
CA (1) CA2077753C (de)
DE (1) DE69132795T3 (de)
IE (1) IE910779A1 (de)
PT (1) PT96994B (de)
WO (1) WO1991013906A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2077753C (en) * 1990-03-09 2000-02-29 Nancy L. Haigwood Purified gp120 composition retaining natural conformation
US7041293B1 (en) 1990-04-03 2006-05-09 Genentech, Inc. HIV env antibodies
CA2078546A1 (en) * 1990-04-03 1991-10-04 Phillip W. Berman Methods and compositions for vaccination against hiv
ATE153380T1 (de) † 1993-01-16 1997-06-15 Manfred Schawaller Verfahren zur gewinnung nativer, oligomerer, glykosylierter ektodomänen viraler membranproteine, deren verwendung, insbesondere als impfstoff gegen hiv
AU700371B2 (en) * 1993-06-07 1999-01-07 Genentech Inc. Hiv envelope polypeptides
EP0751988B1 (de) * 1994-03-22 2000-02-09 The Immune Response Corporation Die hocheffiziente herstellung und isolierung von viruspartikeln
KR100374308B1 (ko) * 1995-07-27 2003-12-18 주식회사 엘지생명과학 재조합차이니스햄스터오바리세포로부터발현된수두바이러스의지피i당단백질의정제방법
US6585979B1 (en) 1996-07-08 2003-07-01 Genentech, Inc. HIV envelope polypeptides and immunogenic composition
WO2000039304A2 (en) 1998-12-31 2000-07-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP1980617A1 (de) 1998-12-31 2008-10-15 Novartis Vaccines and Diagnostics, Inc. Verbesserte Expression von HIV-Polypeptiden und Herstellung virusähnlicher Partikel
AU2596600A (en) 1998-12-31 2000-07-31 Chiron Corporation Modified hiv env polypeptides
CA2452015C (en) 2001-07-05 2012-07-03 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US7556814B2 (en) * 2003-10-23 2009-07-07 Karp Nelson M Immunogenic compositions comprising UV-irradiated, psoralen-inactivated, desialated human immunodeficiency virus (HIV) devoid of CD55 and CD59 in the viral membrane
WO2006011580A1 (ja) * 2004-07-27 2006-02-02 Genomidea, Inc. ウイルスエンベロープの精製方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01120284A (ja) * 1987-11-05 1989-05-12 Shiro Kato Ｈｉｖ不完全粒子および該製造方法
CA2077753C (en) * 1990-03-09 2000-02-29 Nancy L. Haigwood Purified gp120 composition retaining natural conformation

Also Published As

Publication number Publication date
DE69132795T3 (de) 2008-07-10
IE910779A1 (en) 1991-09-11
JPH09227588A (ja) 1997-09-02
WO1991013906A1 (en) 1991-09-19
PT96994B (pt) 1998-07-31
EP0519001B1 (de) 2001-10-31
CA2077753A1 (en) 1991-09-10
EP0519001A1 (de) 1992-12-23
JP2624894B2 (ja) 1997-06-25
DE69132795T2 (de) 2002-06-20
DE69132795D1 (de) 2001-12-13
JPH05505616A (ja) 1993-08-19
PT96994A (pt) 1991-10-31
CA2077753C (en) 2000-02-29
EP0519001B2 (de) 2007-12-19

Similar Documents

Publication Publication Date Title
DE69132795D1 (de) Gereinigtes gp120, in dem seine natürliche konformation erhalten bleibt
DK0731812T3 (da) Fremgangsmåde til isolering af Poly-beta-1-4-N-Acetylglucosamin
ES2146600T3 (es) Condroitinasa, procedimiento para su preparacion y composicion farmaceutica.
DK0458841T3 (da) Fremgangsmåde til anvendelse og fremstilling af peptider
ES2155477T3 (es) Purificacion cromatografica y procedimiento de separacion de acidos nucleicos.
ES2188665T3 (es) Procedimiento para la preparacion de fragmentos de cardiodilatina, fragmentos de cardiodilatina muy purificados y productos intermedios para su preparacion.
RU93046317A (ru) Хиндроитиназа, способ ее получения и содержание ее фармацевтические композиции
CA1133898A (en) Purification of interferon
DK175251B1 (da) Renfremstilling af erythropoietin
SE8402861D0 (sv) Rening av biologiskt material
CN1089609C (zh) 从人血浆分部分离过程产生的馏分中回收免疫球蛋白的方法
DK0567448T4 (da) Fremgangsmåde til fremstilling af faktor VIII
GB2119383A (en) Homogeneous human immune interferon and process therefor
PT98669A (pt) Processo para a preparacao da estrutura proteica da toxina de gelonina vegetal
CA2356894A1 (en) Removal of biological contaminants
JPH0751599B2 (ja) 均質ヒト免疫インターフェロンサブタイプ２６ｋ及びその製造法
CA1270597A (en) Thf compositions
ATE81471T1 (de) Polydisperse native pseudomonas-flagella(h)antigene (fag) und verfahren zu ihrer gewinnung.
CA2139931A1 (en) Purification of Factor IX
DK412389D0 (da) Fremgangsmaade til udvinding af oprenset epi protein fra en fermenteringsoploesning
SE7710201L (sv) Medel med antimalign verkan
BR9710826A (pt) Processo para produçào do interferon epsilon de membrana aminiótica humana e proteìna do interferon epsilon humano de membrana aminiótica humana
KR950002767A (ko) 저분자량-우로가스트론의 정제방법
US6372510B1 (en) Method for removing unconventional transmissible agents from a protein solution
RU93005154A (ru) Белки, фармацевтические композиции, нуклеиновые кислоты, векторы, системы вектор-хозяин, способ получения белка, способы модифицирования функции, способы лечения, способ трансфекции, способ переноса гена, способ измерения активности

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
UEP Publication of translation of european patent specification

Ref document number: 0519001

Country of ref document: EP

EELA Cancelled due to lapse of time